Survey Data Reveals the Need for Improved Communication between Patients and Healthcare Providers about BV

Deepthi | Myequity news | Date : 16-10-2018 12:30:00 IST

Lupin Pharmaceuticals Inc., the U.S. wholly owned subsidiary of Lupin Limited has partnered with the American Sexual Health Association (ASHA) and the National Association of Nurse Practitioners in Women's Health (NPWH) to conduct a two-pronged national online survey among women who have been diagnosed with BV and HCPs who treat women with the condition. Survey findings were presented at the 21st Annual NPWH Premier Women’s Healthcare Conference in San Antonio, TX, from October 10-13, 2018.

According to online survey, although healthcare providers (HCPs) report sharing crucial information on bacterial vaginosis (BV) with patients, the associated risks of the condition remain a mystery to many women, indicating a significant disconnect. With BV known to be the most prevalent gynecologic infection in the U.S., affecting 21 million women each year,  it’s clear that further education is needed to bridge this gap in communication and help women to obtain diagnosis and treatment initiation sooner.

“The incidence of BV is staggering – we know that one in three women will get BV at some point in her life, yet the condition often goes undiagnosed,” says Brooke Faught, nurse practitioner and clinical director of the Women's Institute for Sexual Health (WISH) in Nashville, TN.“As providers, we believe that we’re sharing vital information about BV with our patients, yet these survey findings demonstrate the need to ensure that patients not only understand the symptoms, but the significant risks associated with this most common gynecologic infection.”

“Despite the fact that BV is the most common gynecologic infection, it often goes undiagnosed, so women don’t get the necessary treatment. Due to the risk factors associated with untreated BV, immediate diagnosis and treatment is of high importance,” says Nick Hart, President, Specialty, Lupin Pharmaceuticals, Inc. “By presenting the survey data, we hope to shine a light on the gap between what HCPs believe they’re sharing with patients and the information that patients are actually taking away. If we can close that gap by encouraging a more productive dialogue, we can help shorten the path to diagnosis and treatment.”


While most patients (63 percent) say their HCP discussed general information about BV, far fewer (34 percent) say they discussed the risks associated with BV if left untreated. Women’s health is a major focus area for Lupin Pharmaceuticals, Inc., with the position strengthened through the acquisition of Symbiomix Therapeutics, LLC., a privately held company focused on bringing innovative therapies to market for gynecologic infections that can have serious health consequences, in 2017. In May, Lupin announced the launch of Solosec™, the first new oral antibiotic to treat BV in more than a decade and the first and only single-dose oral therapy for BV.

The issues uncovered by the survey don’t end with patient-HCP communication; the survey also identified the issue of treatment adherence with some patients. While most patients report using their treatment as prescribed (90 percent for those who used an oral antibiotic; 87 percent for those who used vaginal cream), nearly three in 10 (29 percent) who have used prescription BV treatments feel the currently available therapies for BV are very difficult to complete. However, the vast majority of women with BV (91 percent) would be open to trying new treatment options for BV.

“The results demonstrate the need for clearer and more open dialogue between HCPs and patients to not only facilitate prompt treatment, but also to encourage treatment compliance,” concludes Faught. “Additionally, HCPs must stay informed about less cumbersome treatment options that may help patients adhere.”

About Lupin Limited:


Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded &generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.


More from Myequity